Literature DB >> 24227784

The kinetics of myelin antigen uptake by myeloid cells in the central nervous system during experimental autoimmune encephalomyelitis.

Rebecca A Sosa1, Cathi Murphey, Niannian Ji, Astrid E Cardona, Thomas G Forsthuber.   

Abstract

Induction of experimental autoimmune encephalomyelitis (EAE) in susceptible animals requires reactivation of encephalitogenic CD4(+) T cells by APCs in the CNS. However, it has remained unresolved from where APCs in the CNS acquire myelin Ag for T cell activation and under which conditions, that is, whether only during EAE or also in the naive CNS. In this study, we investigated the kinetics of myelin Ag uptake by CNS APCs during EAE and in the naive CNS. Our results show that during EAE CX3CR1(+)CD11b(+) microglia were the first APCs in the CNS to contain myelin Ag upon induction of disease, albeit in very small numbers. Dendritic cells (DCs) arrived in the CNS in sizable numbers significantly later (day 5 postimmunization), without detectable myelin Ag, but acquired it by day 7 postimmunization. Furthermore, a sharp increase in neuroantigen-containing DCs coincided with the onset of EAE symptoms. Importantly, in naive mice a low but consistent number of microglia contained myelin Ag, suggesting release by oligodendrocytes under steady state conditions. Although microglia isolated from naive brain and spinal cord did not elicit a strong CD4(+) T cell response in vitro, myelin Ag-containing microglia may still play a local role in modulating encephalitogenic CD4(+) T cell responses in early EAE prior to the arrival of other professional APCs, such as DCs. Finally, newly arriving DCs in the CNS not yet loaded with myelin Ag before the onset of EAE may be a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24227784      PMCID: PMC3891847          DOI: 10.4049/jimmunol.1300771

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  The enhanced antigen-specific production of cytokines induced by pertussis toxin is due to clonal expansion of T cells and not to altered effector functions of long-term memory cells.

Authors:  C L Shive; H Hofstetter; L Arredondo; C Shaw; T G Forsthuber
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

Review 2.  Are astrocytes central players in the pathophysiology of multiple sclerosis?

Authors:  Jacques De Keyser; Esther Zeinstra; Elliot Frohman
Journal:  Arch Neurol       Date:  2003-01

3.  The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.

Authors:  Olaf Stüve; Sawsan Youssef; Anthony J Slavin; Chelsea L King; Juan Carlos Patarroyo; David L Hirschberg; W June Brickey; Jeanne M Soos; Janet F Piskurich; Harold A Chapman; Scott S Zamvil
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

4.  Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation.

Authors:  M K Matyszak; S Denis-Donini; S Citterio; R Longhi; F Granucci; P Ricciardi-Castagnoli
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

5.  Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice.

Authors:  D Sun; J N Whitaker; Z Huang; D Liu; C Coleclough; H Wekerle; C S Raine
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

6.  Role of astrocytes in antigen presentation and naive T-cell activation.

Authors:  A Cornet; E Bettelli; M Oukka; C Cambouris; V Avellana-Adalid; K Kosmatopoulos; R S Liblau
Journal:  J Neuroimmunol       Date:  2000-07-01       Impact factor: 3.478

7.  Parenchymal microglia of naïve adult C57BL/6J mice express high levels of B7.1, B7.2, and MHC class II.

Authors:  Guang Xian Zhang; Jifen Li; Elvira Ventura; Abdolmohamad Rostami
Journal:  Exp Mol Pathol       Date:  2002-08       Impact factor: 3.362

8.  Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis.

Authors:  Pia Kivisäkk; Jaime Imitola; Stine Rasmussen; Wassim Elyaman; Bing Zhu; Richard M Ransohoff; Samia J Khoury
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

9.  Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.

Authors:  M Krogsgaard; K W Wucherpfennig; B Cannella; B E Hansen; A Svejgaard; J Pyrdol; H Ditzel; C Raine; J Engberg; L Fugger; B Canella
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

10.  A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis.

Authors:  E S Huseby; D Liggitt; T Brabb; B Schnabel; C Ohlén; J Goverman
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

View more
  30 in total

Review 1.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

Review 2.  Characteristics and critical function of CD8+ T cells in the Toxoplasma-infected brain.

Authors:  Tyler A Landrith; Tajie H Harris; Emma H Wilson
Journal:  Semin Immunopathol       Date:  2015-04-22       Impact factor: 9.623

3.  Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection.

Authors:  Sahar Salehi; Rebecca A Sosa; Yi-Ping Jin; Shoichi Kageyama; Michael C Fishbein; Enrique Rozengurt; Jerzy W Kupiec-Weglinski; Elaine F Reed
Journal:  Am J Transplant       Date:  2017-11-23       Impact factor: 8.086

4.  Focal transient CNS vessel leak provides a tissue niche for sequential immune cell accumulation during the asymptomatic phase of EAE induction.

Authors:  Deborah S Barkauskas; R Dixon Dorand; Jay T Myers; Teresa A Evans; Kestutis J Barkauskas; David Askew; Robert Purgert; Alex Y Huang
Journal:  Exp Neurol       Date:  2015-02-20       Impact factor: 5.330

5.  Human-derived natural antibodies: biomarkers and potential therapeutics.

Authors:  Xiaohua Xu; Sher May Ng; Eamonn Hassouna; Arthur Warrington; Sang-Hyun Oh; Moses Rodriguez
Journal:  Future Neurol       Date:  2015

Review 6.  Do not judge a cell by its cover--diversity of CNS resident, adjoining and infiltrating myeloid cells in inflammation.

Authors:  Stefanie M Brendecke; Marco Prinz
Journal:  Semin Immunopathol       Date:  2015-08-07       Impact factor: 9.623

7.  IFN-γ ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation.

Authors:  Rebecca A Sosa; Cathi Murphey; Rachel R Robinson; Thomas G Forsthuber
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

8.  Serum Neuroinflammatory Disease-Induced Central Nervous System Proteins Predict Clinical Onset of Experimental Autoimmune Encephalomyelitis.

Authors:  Itay Raphael; Johanna Webb; Francisco Gomez-Rivera; Carol A Chase Huizar; Rishein Gupta; Bernard P Arulanandam; Yufeng Wang; William E Haskins; Thomas G Forsthuber
Journal:  Front Immunol       Date:  2017-07-17       Impact factor: 7.561

Review 9.  When encephalitogenic T cells collaborate with microglia in multiple sclerosis.

Authors:  Yifei Dong; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2019-09-16       Impact factor: 42.937

10.  Disulfide High-Mobility Group Box 1 Drives Ischemia-Reperfusion Injury in Human Liver Transplantation.

Authors:  Rebecca A Sosa; Allyson Q Terry; Fady M Kaldas; Yi-Ping Jin; Maura Rossetti; Takahiro Ito; Fang Li; Richard S Ahn; Bita V Naini; Victoria M Groysberg; Ying Zheng; Antony Aziz; Jessica Nevarez-Mejia; Ali Zarrinpar; Ronald W Busuttil; David W Gjertson; Jerzy W Kupiec-Weglinski; Elaine F Reed
Journal:  Hepatology       Date:  2020-10-30       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.